Index

Note: Page numbers of article titles are in **boldface** type.

A

Activities of daily living assessment, 447
AD. See Alzheimer disease.
Adaptive designs, for clinical trials, 446
ADAS-Cog (Alzheimer Disease Assessment Scale Cognitive Subscale) scores, 446–447, 486
ADCS–Clinical Global Impression of Change, 448
ADL-Prevention Instrument, 447
Aging, amyloid imaging in, 384–385
Alzheimer Association
   Alzheimer disease diagnosis criteria of, 440
   amyloid imaging criteria for, 388–389
Alzheimer disease
   definition of, 364
   diagnosis of
      amyloid imaging with, 377–398
      cerebrospinal fluid biomarkers for. See Cerebrospinal fluid biomarkers.
      clinical applications in, 477–484
      cognitive approaches to, 425–438
      ethical issues in, 461–464, 482
      in late stage, 460
      in preclinical stages, 371–372, 439–457
   International Work Group criteria for, 363–368, 477–484
   magnetic resonance imaging for. See Magnetic resonance imaging.
   positron emission tomography for. See Positron emission tomography.
   psychological implications of, 459–475
   recent developments in, 378–379
   timing of, 460
   early-onset, 467–469, 486
   genetic testing for, 468–469
   incidence of, 439
   phases of, 364
   progression of, 364–365
   stages of, 401
Alzheimer Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores, 446–447, 486
Alzheimer Prevention Initiative, 443
Alzheimer's Association Quality Control Program, 374
Alzheimer's Disease Assessment Scale, Cognitive Subscale subtests, 431–432
Alzheimer's Disease Cooperative Study trial, 443–444
Alzheimer's Disease Functional Assessment of Change Scale, 447
Alzheimer's Disease Neuroimaging Initiative, 403, 448
Amyloid, 377–398
  Aβ
  as biomarker, 370–372, 374
  PET imaging for, 382–387
  as biomarker, 370, 372, 374, 445, 476–477
  in aging, 384–385
  in Alzheimer disease
    PET imaging for, 479
    appropriate use of, 387–389
    findings in, 382–383
    postmortem correlation and, 383–384
    radiotracers for, 379–382, 479
    versus other investigations, 385–386
  risk factors for, 386
  in dementia differential diagnosis, 386–387
  in mild cognitive impairment, 384–385
Anosognosia, 463
Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease trial, 440
Apolipoprotein E
  as biomarker, 442–443, 445
  in amyloid deposition, 386
Ashford review, of cognitive tests, 425–427
Attention, 428–429
Automated data-driven methods, in MRI, 405, 407–408
Automated region-driven methods, in MRI, 406–407
Autonomy, in Alzheimer diagnosis, 482
Autosomal Alzheimer disease, clinical trials for, 441–444
AZD4694, F-18 labeled, for PET, 380–382

B
Beneficence, in Alzheimer diagnosis, 482
The Benefits of Early Diagnosis and Intervention, 477
Biomarkers, 379, 478–481. See also Cerebrospinal fluid biomarkers.
  in mild cognitive impairment, 445
Braak stages, of Alzheimer disease, 401–403
Brain, volume of, MRI for, 401–403
Brief Assessment of Cognition in Schizophrenia, 433
Brief Visual Memory Test, 432

C
CANATAB Pattern Recognition Test, 432–433
Caregivers, Alzheimer disease psychological implications of, 460–469
CDR Scale Sum of Boxes measure, 448
CDR System Picture Recognition Test, 432
Cerebrospinal fluid biomarkers, 364, 369–376, 476–477, 481
  advantages of, 370
  clinical applications of, 372–374
  in preclinical AD, 371–372
  in prodromal AD, 371
temporal evolution of, 372
validated, 370–371
versus amyloid imaging, 385–386
Cholinergic nuclei, MRI for, 409
Clinical Global Impression of Change plus Caregiver Input checklist, 448
Clinical trials, in preclinical AD, 439–457
agents considered for, 449
implementation of, 449–451
in asymptomatic persons, 441–446
in mild cognitive impairment, 444–446
in prodromal populations, 444, 446–449
outcome measures of, 446–449
Clinician’s Interview-Based Impression of Change–Plus, 448
Cognitive decline, fluorodeoxyglucose-PET for, 486
Cognitive testing, 425–438
   cognition domains in, 427–430
current models of, 432–433
historical review of, 425–427
needs for, 430–432
recent reviews of, 433–434
Communication, in AD diagnosis, 462, 464–467
Complexity-based disease indicators, in MRI, 411–412
Computed tomography, for Alzheimer diagnosis, 490–491
Confrontation naming, 428
Consortium to Establish a Registry for Alzheimer’s Disease, 480
Cortical atrophy, 407–408
Crenezumab, 443

D
Deformation-based approaches, in MRI, 408
Dementia, differential diagnosis of, 386–387
DESCRIPA (Development of Screening guidelines and Criteria for Predementia Alzheimer’s disease) study, 371
Diffusion tensor imaging, 409–410
Disability Assessment for Dementia scale, 447
Dominantly Inherited Alzheimer Network, 443
Donepezil, 445

E
Early-onset Alzheimer disease, 467–469, 486
Echo planar imaging, 409–410
Emotional implications, of early-onset AD, 467–468
Enabling anticipation, of incurable disorders, 462–463
Entorhinal cortex volumetry, 403, 405
Enzyme-linked immunosorbent assay, for biomarkers, 371
Episodic memory, 428, 432, 480
Ethical issues
   in AD disclosure, 461–464
   in early AD diagnosis, 482
Index

European Alzheimer’s Disease Consortium, 403
European Medicines Agency, 447
Executive function, 429–430

F
Familial Alzheimer disease
   biomarkers in, 372
   clinical trials for, 441–444
Florbetaben, F-18 labeled, for PET, 380–382, 384
Florbetapir, F-18 labeled, for PET, 380–382, 384, 479
Fluorodeoxyglucose-PET, for Alzheimer diagnosis, 485–486
   differential, 487
   early, 486–487
   in multimodal approach, 490–491
   lack of widespread use of, 490
   predicting progression, 488
   prodromal, 486
   versus amyloid imaging, 385
   versus cognitive decline, 487–488
Flutemetamol, F-18 labeled, for PET, 380–382, 384, 479
Food and Drug Administration, outcome measures of, 448
Free and Cued Selective Reminding Test, 364, 480
Frontotemporal dementia
   amyloid imaging for, 386–387
   versus Alzheimer disease, 487
Functional magnetic resonance imaging, 410–411

G
Gantenerumaab, 444
Genetic factors
   in Alzheimer disease, 468–469
   in amyloid deposition, 386

H
Hanoi puzzle, 429
Hippocampus, volume of, 403, 405–406

I
Ideational praxis, 428
Informed consent, in Alzheimer diagnosis, 482
International Working Group criteria, for Alzheimer disease diagnosis, 363–368, 440
   advantages of, 366
   biologic side of, 478–479
   clinical applications of, 477–484
   clinical side of, 480
   description of, 364–366
   ethical issues in, 482
   implications of, 367
Language domain, of cognition, 428
Lewy body disease
  amyloid imaging for, 387
  versus Alzheimer disease, 487
Limbic stage, 401
Logical Memory test, 480
Logopenic aphasia, 387
LY2886721, 443

Machine-learning techniques, in MRI, 412–413
Magnetic resonance imaging, for Alzheimer diagnosis, 399–424, 481, 488–491
  advanced image analysis in, 405, 408–409
  automated data-driven methods in, 405, 407–408
  automated region-driven methods in, 406–407
  complexity-based indicators in, 411–412
  cortical thickness measurement in, 405
  diffusion-weighted imaging in, 409–410
  entorhinal cortex volumetry in, 403, 405
  functional, 410–411
  hippocampus subfields in, 403–404, 406
  machine-learning techniques in, 412–413
  manual volumetry om, 401–403
  multimodal data-processing strategies in, 412–413
  versus amyloid imaging, 386
  visual rating scales in, 401, 404–405
  whole brain volume measurement in, 405
Mail-In Cognitive Function Screening Instrument, 448
Manual volumetry, in MRI, 401–403
Medial temporal lobe, volumetry of, 402–403
Memory, 427–428, 432, 480
Mild cognitive impairment
  amyloid imaging in, 384–385
  biomarkers in, 481
  clinical trials for, 444–445, 447
  cognitive testing in, 431–432
  diagnosis of, 379
  MRI for, 402–403, 408
Mini Mental Status Examination (MMSE), 432–433, 447
Moral pain, in AD disclosure, 464
MRI. See Magnetic resonance imaging.
Multimodal data-processing, in MRI, 412–413

NAV4694 (AZD4694, F-18 labeled), for PET, 380–382, 384
Neocortical stage, 401
Neuropsychiatric Inventory, 449
Neuropsychiatric symptoms, 448–449
Neuropsychological Assessment Battery, 433
Neuropsychological test battery, 447
Nonmalfeasance, in Alzheimer disease diagnosis, 482

P

Parkinson disease
  amyloid imaging for, 387
  versus Alzheimer disease, 487
PET. See Fluorodeoxyglucose-PET.
Phosphorylated tau, as biomarker, 370–372, 481
Pioglitazone, 443
Pittsburgh Compound B, C-11 labeled, for PET, 380–386
Planning function, 429–430
Positron emission tomography. See also Fluorodeoxyglucose-PET.
  for amyloid imaging, 479
  in aging, 384–385
  in Alzheimer disease, 379–386
  in dementia differential diagnosis, 386–387
  in mild cognitive impairment, 384–385
  radiotracers for, 379–382, 479
Praxis, 428
Preclinical Alzheimer disease
  biomarkers in, 371–372
  clinical trials in, 439–457
Presenilin defects, in amyloid deposition, 386
Prevent Alzheimer Disease 2020, 433–434
Preventive measures, for AD, testing for, 440–441
Probable Alzheimer disease dementia with evidence of the AD pathophysiologic process, 378
Problem solving, 429–430
Prodromal Alzheimer disease, 365
  biomarkers in, 371
  clinical trials for, 444, 446–449
  diagnosis of, 379
  fluorodeoxyglucose-PET for, 486
Psychological implications, of early diagnosis, 459–475
  complex communication in, 464–465
  consultations for, 465–467
  current reality of, 461
  enabling anticipation in, 462–463
  for optimal experience, 465
  guidelines in favor of, 460
  in early-onset dementia, 467–468
  individual patient and caregiver personalities in, 465
  moral pain, 464
  patient awareness in, 463
  patient right to know in, 463–464
  research needs for, 469–471
  suicidal risk and, 464
training resources for, 469–471
uncertainty in, 462

**R**
Radiotracers, for amyloid PET, 379–382, 479
Reaction time paradigms, 429
Rentz and Weintraub review, of cognitive tests, 425–427
Resource Utilization in Dementia instrument, 449
Rey Auditory Verbal Learning Test, 480
Rey-Osterrieth Complex Figure, 432

**S**
Screen failures, 451
Semantic memory, 428
Seretase, as biomarker, 442
Set-shifting test, 429
Society of Nuclear Medicine and Molecular Imaging, amyloid imaging criteria for, 388–389
Subcortical nuclei, MRI for, 408
Suicidal risk, 464
Swedish Brain Power project, 371
Synuclein lesions, 387

**T**
Tau proteins, as biomarkers, 370–372, 481
Total tau, as biomarker, 370–372, 481
Trail-making test, 429
Transentorhinal stage, 401
Translocase of outer mitochondrial membrane 40 homolog gene, 443

**U**
US ADNI (US Alzheimer’s Disease Neuroimaging Initiative) study, 371

**V**
Visual Paired Associates learning test, 432
Visual rating scales, for MRI, 401, 404–405
Vitamin E, 445
Voxel-based morphometry, in MRI, 405, 407–408

**W**
Wechsler Memory Scale, 480
Working memory, 428